VarMap™ Pan-Cancer NGS Panel is a comprehensive cancer mutation liquid biopsy panel to detect 0.1% VAF on the MiniSeq and MiSeq requiring only 1M reads. It covers 337 hotspots in 61 genes with clinical high-significance in many cancer types and includes detection of over 6500 COSMIC mutations including JAK2 V617F, BRAF V600E, KRAS G12D/G12V/G12C, EGFR exon 19 deletions and insertions, EGFR T790M, EGFR L858R, and TP53 R248Q. The VarMapTM Pan-Cancer NGS Panel enables highly sensitive mutation detection and quantitation for cancer patients.

Cancer:

Leukemia, Lymphoma, Solid Tumor

Gene:

AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), AR (Androgen receptor), ATM (ATM serine/threonine kinase), BRAF (B-raf proto-oncogene), CCND1 (Cyclin D1), CDK4 (Cyclin-dependent kinase 4), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), CHEK2 (Checkpoint kinase 2), CTNNB1 (Catenin (cadherin-associated protein), beta 1), DDR2 (Discoidin domain receptor 2), EGFR (Epidermal growth factor receptor), ER (Estrogen receptor), ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3), ERBB4 (erb-b2 receptor tyrosine kinase 4), EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit), FBXW7 (F-Box And WD Repeat Domain Containing 7), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FGFR4 (Fibroblast growth factor receptor 4), FLT3 (Fms-related tyrosine kinase 3), GNA11 (G Protein Subunit Alpha 11), GNAQ (G Protein Subunit Alpha Q), GNAS (GNAS Complex Locus), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), JAK1 (Janus Kinase 1), JAK2 (Janus kinase 2), JAK3 (Janus Kinase 3), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAP2K2 (Mitogen-activated protein kinase kinase 2), MET (MET proto-oncogene, receptor tyrosine kinase), MLH1 (MutL homolog 1), MYC (V-myc avian myelocytomatosis viral oncogene homolog), MYCN (MYCN Proto-Oncogene BHLH Transcription Factor), MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), NPM1 (Nucleophosmin 1), NRAS (Neuroblastoma RAS viral oncogene homolog), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), PTEN (Phosphatase and tensin homolog), PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase), RB1 (RB Transcriptional Corepressor 1), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), SF3B1 (Splicing Factor 3b Subunit 1), SMAD4 (SMAD family member 4), SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), SMO (Smoothened Frizzled Class Receptor), STK11 (Serine/threonine kinase 11), TP53 (Tumor protein P53), mTOR (Mechanistic target of rapamycin kinase)

Method:

Next-Generation Sequencing (NGS)

TEST:VarMap™ Pan-Cancer NGS Panel

Details

TEST:
VarMap™ Pan-Cancer NGS Panel